OSE Immunotherapeutics' Tedopi Combinations Meet Primary Endpoint in Phase 2 Lung Cancer Trial

PUBT · 2d ago
OSE Immunotherapeutics' Tedopi Combinations Meet Primary Endpoint in Phase 2 Lung Cancer Trial
  • OSE Immunotherapeutics reported positive topline results from its Phase 2 Combi-TED trial of Tedopi as second-line treatment for metastatic non-small cell lung cancer.
  • Tedopi combined with either docetaxel or nivolumab improved one-year survival versus docetaxel alone, meeting the trial’s primary endpoint.
  • No unexpected safety signals were observed.
  • Results will be presented October 25, 2026, at the European Society for Medical Oncology annual meeting in Madrid.
  • The Phase 3 ARTEMIA trial comparing Tedopi monotherapy with docetaxel is recruiting patients, with results expected in early 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190130PRIMZONEFULLFEED1001278426) on October 19, 2026, and is solely responsible for the information contained therein.